Zentalis Q2 Loss Widens to $0.59/Share as R&D Costs Surge
ZNTL has more than doubled off its 52-week low of $1.212.
Summary
Zentalis reported a Q2 net loss of $0.59 per share, wider than expected, driven by higher R&D spending tied to a milestone payment for the ASPENOVA Phase 3 trial and increased clinical costs. The company completed enrollment in the DENALI Part 2a and 2b trials, advancing its accelerated approval strategy for azenosertib, with topline data expected in 1H 2027. Cash of $174.6 million provides runway into late 2027, consistent with prior guidance. The wider loss and rising expenses raise concerns about cash burn, though the maintained runway and regulatory alignment with the FDA on an accelerated pathway are positive. This follows the Q1 2026 results which showed a reduced net loss, making the Q2 reversal notable.
At the time of this announcement, ZNTL was trading at $4.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $355.9M. The 52-week trading range was $1.21 to $6.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.